Advanced Filters
noise

Junggu, Korea, Republic of Clinical Trials

A listing of Junggu, Korea, Republic of clinical trials actively recruiting patients volunteers.

Found 1,412 clinical trials
J Jun-Hyung Cho, M.D.

Tegoprazan- Versus PPI-based H. Pylori Eradication

In 2015, vonoprazan, a potassium-competitive blocker (P-CAB), was launched in Japan and used as an alternative for proton pump inhibitors (PPIs) for eradicating Helicobacter pylori. In recent studies, vonoprazan-based triple therapy significantly increased the eradication rate from 72.8% to 87.9%, compared to PPI treatment group. Accordingly, the Japanese Helicobacter treatment …

20 - 80 years of age All Phase N/A
N Neuroventi

Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder

This is a multicenter, randomized, double-blind, placebo-controlled, therapeutic exploratory Phase 2 clinical trial designed to evaluate the efficacy and safety of NV01-A02 in pediatric participants diagnosed with Autism Spectrum Disorder (ASD).

6 - 15 years of age All Phase 2

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

18 years of age All Phase 1/2
H Heejoon Jeong, MD

Postoperative Vocal Cord Palsy Between Double-lumen Endobronchial Tube and Bronchial Blocker for Robot-assisted Esophagectomy

The goal of this clinical trial is to investigate whether the use of bronchial blocker could reduce the incidence of postoperative vocal cord palsy than the use of double-lumen endobronchial tube in robot-assisted esophagectomy.

19 years of age All Phase N/A
E Eunseo Sun, Bachelor's

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1). The main questions it aims to answer are: How well participants are able tolerate different doses of PAS-004, and What side effects PAS-004 might …

18 years of age All Phase 1
C Chung Ang University Hospital

Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24

19 years of age All Phase 3

Predicting Fall Risk in Stroke Patients Using a Machine Learning Model and Multi-Sensor Data

The study assesses a machine learning model developed to predict fall risk among stroke patients using multi-sensor signals. This prospective, multicenter, open-label, sponsor-initiated confirmatory trial aims to validate the safety and efficacy of the model which utilizes electromyography (EMG) signals to categorize patients into high-risk or low-risk fall categories. The …

19 years of age All Phase N/A
H Hee Jo Baek, Ph.D

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

This study is open-label, multi-center, prospective study, which targets childhood patients with relapsed acute lymphostatic leukemia including bone marrow recurrence. Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for relapsed acute lymphoblastic leukemia in children and adolescents.

1 - 22 years of age All Phase 2

A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.

19 - 64 years of age All Phase 1/2
H Hyoung Jin Kang, MD, PhD

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

Clinical and genetic factors consistent with High risk : Induction → Consolidation BM MRD \< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance BM MRD ≥ 0.01% after …

1 - 19 years of age All Phase 2

Simplify language using AI